Answers are grounded in this paper and cite their sources.
Cross-sectional survey explores self-reported behavior changes in COPD patients for trial design, suggesting improved patient engagement.
Rationale The COVID-19 pandemic dramatically altered the lived experience of people with COPD, affecting their health behaviors, care access and perspectives on research participation (Padala, 2020). Understanding these patient-driven changes is essential for designing relevant, feasible, and patient-centered clinical trials. Methods A U.S. cross-sectional survey was conducted among COPD patients identified through the COPD Foundation patient platforms between October and December 2024. The survey captured demographic data, healthcare utilization, lifestyle adaptations, psychosocial impacts, and attitudes toward health monitoring and engagement since the pandemic’s onset. Open-ended responses were described overall and in specific subgroups; thematic analysis was used for patient priorities and barriers. Results Of the 336 respondents, the majority (81%) were aged ≥65 and lived independently, either alone (32%) or with others (43%). Most had been diagnosed with COPD after age 50. Compared to pre-pandemic practices, telemedicine adoption increased substantially (figure 1): 49% began using telemedicine only after the pandemic, while 35% had tried it previously. Most respondents reported reduced physical activity (60%), increased social distancing in public spaces (43%), and new or intensified mask use (76% started masking after the pandemic began). Approximately 70% described heightened anxiety and stress, often linked to reduced social support, uncertainty of healthcare management, and disrupted routines. Respondents reported increased self-monitoring of health (41% more likely to track symptoms, oxygen, or blood pressure). Regarding recommended vaccinations, 81% and 66% of participants were very likely to get their flu and COVID-19 vaccines, respectively, while other vaccines including RSV and pneumococcal were very likely in at least 50% of those surveyed. Qualitative responses highlighted a strong desire for flexible healthcare options, clear communication, and research that acknowledges the realities of living with COPD during and after the pandemic. Barriers to trial participation included technology access and persistent concerns about exposure risk. Despite these challenges, most respondents remained engaged with their healthcare teams and expressed willingness to participate in research if protocols reflected their lived experiences and preferences. Conclusion This survey underscores the necessity of bringing patient voices into the clinical trial design process to ensure that evolving behaviors and needs are considered to facilitate patient recruitment and retention in the post-pandemic era. Figure1: Proportion of patients reporting change of telemedicine use since the start of the pandemic References Padala PR, Jendro AM, Padala KP. Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives. JMIR Public Health Surveill 2020;6(2):e18887 This abstract is funded by: Chiesi
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: